Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis

References

• Lamb CA, Kennedy NA, Raine T, IBD guidelines eDelphi consensus group, et al. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):S1–S106.
   PubMed Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390(10114):2769–2778.
   PubMed Web of Science ®Google Scholar
• Yang S-K, Yun S, Kim J-H, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, korea, 1986–2005: a KASID study. Inflamm Bowel Dis. 2008;14(4):542–549.
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Rifas-Shiman SL, Porter C, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135(6):1907–1913.
   PubMed Web of Science ®Google Scholar
• Höie O, Wolters F, Riis L, European Collaborative Study Group of Inflammatory Bowel Disease (EC-IBD), et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a european-wide population-based cohort. Am J Gastroenterol. 2007;102(8):1692–1701.
   PubMed Web of Science ®Google Scholar
• Andersen NN, Jess T. Has the risk of colorectal cancer in inflammatory bowel disease decreased? World J Gastroenterol. 2013;19(43):7561–7568.
   PubMed Web of Science ®Google Scholar
• Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133(4):1099–1105.
   PubMed Web of Science ®Google Scholar
• Kato J, Yoshida T, Hiraoka S. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Rev Clin Immunol. 2019;15(6):667–677.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-Target. Am J Gastroenterol. 2015;110(9):1324–1338.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194–1201.
   PubMed Web of Science ®Google Scholar
• Bryant RV, Winer S, Travis SPL, et al. Systematic review: histological remission in inflammatory bowel disease. Is “complete' remission the new treatment paradigm? An IOIBD initiative”. J Crohns Colitis. 2014;8(12):1582–1597.
   PubMed Web of Science ®Google Scholar
• Matts SG. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med. 1961;30:393–407.
   PubMedGoogle Scholar
• Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J. 1964;1(5375):89–92.
   PubMed Web of Science ®Google Scholar
• Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298(6666):82–86.
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–1629.
   PubMed Web of Science ®Google Scholar
• Travis SPL, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the ulcerative colitis endoscopic index of severity (UCEIS). Gut. 2012;61(4):535–542.
   PubMed Web of Science ®Google Scholar
• Samuel S, Bruining DH, Loftus EV, et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol. 2013;11(1):49–54.e1.
   PubMed Web of Science ®Google Scholar
• Yoon H, Jangi S, Dulai PS, et al. Incremental benefit of achieving endoscopic and histologic remission in patients with ulcerative colitis: a systematic review and meta-analysis. Gastroenterology. 2020;159(4):1262–1275.e7.
   PubMed Web of Science ®Google Scholar
• Boal Carvalho P, Dias de Castro F, Rosa B, et al. Mucosal healing in ulcerative colitis–when zero is better. ECCOJC. 2016;10(1):20–25.
   Web of Science ®Google Scholar
• Barreiro-de Acosta M, Vallejo N, de la Iglesia D, et al. Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (Mayo 0 vs 1): a longitudinal cohort study. ECCOJC. 2016;10(1):13–19.
   Web of Science ®Google Scholar
• Fukuda T, Naganuma M, Sugimoto S, et al. Efficacy of therapeutic intervention for patients with an ulcerative colitis Mayo endoscopic score of 1. Inflamm Bowel Dis. 2019;25(4):782–788.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Scott FI, Fogt FF, et al. Endoscopic and histological assessment, correlation, and relapse in clinically quiescent ulcerative colitis (MARQUEE). Inflamm Bowel Dis. 2021;27(2):207–214.
   PubMed Web of Science ®Google Scholar
• Saigusa K, Matsuoka K, Sugimoto S, et al. Ulcerative colitis endoscopic index of severity is associated with long-term prognosis in ulcerative colitis patients treated with infliximab. Dig Endosc. 2016;28(6):665–670.
   PubMed Web of Science ®Google Scholar
• Ikeya K, Hanai H, Sugimoto K, et al. The ulcerative colitis endoscopic index of severity more accurately reflects clinical outcomes and long-term prognosis than the Mayo endoscopic score. ECCOJC. 2016;10(3):286–295.
   Web of Science ®Google Scholar
• Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120(1):13–20.
   PubMed Web of Science ®Google Scholar
• Neurath MF, Travis SPL. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61(11):1619–1635.
   PubMed Web of Science ®Google Scholar
• Magro F, Langner C, Driessen A, European Crohn's and Colitis Organisation (ECCO), et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7(10):827–851.
   PubMed Web of Science ®Google Scholar
• Hefti MM, Chessin DB, Harpaz NH, et al. Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum. 2009;52(2):193–197.
   PubMed Web of Science ®Google Scholar
• Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126(2):451–459.
   PubMed Web of Science ®Google Scholar
• Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol. 2012;107(11):1684–1692.
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, International Organization for the Study of IBD, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583.
   PubMed Web of Science ®Google Scholar
• Sands B, Sandborn W, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. The. N Engl J Med. 2019;381(13):1201–1214.
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Petrillo M, Imbesi V, et al. Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol Ther. 1999;13(3):373–379.
   PubMed Web of Science ®Google Scholar
• Feakins RM, British Society of Gastroenterology. Inflammatory bowel disease biopsies: updated british society of gastroenterology reporting guidelines. J Clin Pathol. 2013;66(12):1005–1026.
   PubMed Web of Science ®Google Scholar
• Ozaki R, Kobayashi T, Okabayashi S, et al. Histological risk factors to predict clinical relapse in ulcerative colitis with endoscopically normal mucosa. J Crohns Colitis. 2018;12(11):1288–1294.
   PubMed Web of Science ®Google Scholar
• Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991;32(2):174–178.
   PubMed Web of Science ®Google Scholar
• Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47(3):404–409.
   PubMed Web of Science ®Google Scholar
• Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, et al. Development and validation of the nancy histological index for UC. Gut. 2017;66(1):43–49.
   PubMed Web of Science ®Google Scholar
• Mosli MH, Feagan BG, Zou G, et al. Development and validation of a histological index for UC. Gut. 2017;66(1):50–58.
   PubMed Web of Science ®Google Scholar
• Cushing KC, Tan W, Alpers DH, et al. Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission. Aliment Pharmacol Ther. 2020;51(3):347–355.
   PubMed Web of Science ®Google Scholar
• Jauregui-Amezaga A, López-Cerón M, Aceituno M, et al. Accuracy of advanced endoscopy and fecal calprotectin for prediction of relapse in ulcerative colitis: a prospective study. Inflamm Bowel Dis. 2014;20(7):1187–1193.
   PubMed Web of Science ®Google Scholar
• Okabayashi S, Kobayashi T, Nakano M, et al. A simple 1-Day Colon capsule endoscopy procedure demonstrated to be a highly acceptable monitoring tool for ulcerative colitis. Inflamm Bowel Dis. 2018;24(11):2404–2412.
   PubMed Web of Science ®Google Scholar
• Usui S, Hosoe N, Matsuoka K, et al. Modified bowel preparation regimen for use in second-generation colon capsule endoscopy in patients with ulcerative colitis. Dig Endosc. 2014;26(5):665–672.
   PubMed Web of Science ®Google Scholar
• Matsubayashi M, Kobayashi T, Okabayashi S, et al. Determining the usefulness of capsule scoring of ulcerative colitis in predicting relapse of inactive ulcerative colitis. Journal of Gastroenterology and Hepatology. 2021;36(4):943–950.
   PubMed Web of Science ®Google Scholar
• Li C-Q, Xie X-J, Yu T, et al. Classification of inflammation activity in ulcerative colitis by confocal laser endomicroscopy. Am J Gastroenterol. 2010;105(6):1391–1396.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Kuroki F, Mizuno M, et al. Application of magnifying chromoscopy for the assessment of severity in patients with mild to moderate ulcerative colitis. Gastrointest Endosc. 1997;46(5):400–405.
   PubMed Web of Science ®Google Scholar
• Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003;124(4):880–888.
   PubMed Web of Science ®Google Scholar
• Hurlstone DP, Sanders DS, McAlindon ME, et al. High-magnification chromoscopic colonoscopy in ulcerative colitis: a valid tool for in vivo optical biopsy and assessment of disease extent. Endoscopy. 2006;38(12):1213–1217.
   PubMed Web of Science ®Google Scholar
• Fujiya M, Saitoh Y, Nomura M, et al. Minute findings by magnifying colonoscopy are useful for the evaluation of ulcerative colitis. Gastrointest Endosc. 2002;56(4):535–542.
   PubMed Web of Science ®Google Scholar
• Klenske E, Atreya R, Hartmann A, et al. Magnification endoscopy with optical chromoendoscopy shows strong correlation with histologic inflammation in patients with inflammatory bowel disease. Endosc Int Open. 2019;07(08):E1018–26.
   Web of Science ®Google Scholar
• Watanabe C, Sumioka M, Hiramoto T, et al. Magnifying colonoscopy used to predict disease relapse in patients with quiescent ulcerative colitis. Inflamm Bowel Dis. 2009;15(11):1663–1669.
   PubMed Web of Science ®Google Scholar
• Nishio Y, Ando T, Maeda O, et al. Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis. Gut. 2006;55(12):1768–1773.
   PubMed Web of Science ®Google Scholar
• Isomoto H, Uehara R, Hayashi T, et al. Magnifying endoscopic findings can predict clinical outcome during long-term follow-up of more than 12 months in patients with ulcerative colitis. Gastroenterol Res Pract. 2013;2013:671576.
   PubMed Web of Science ®Google Scholar
• Hiyama S, Iijima H, Sakakibara Y, et al. Endoscopic alterations in Peyer's patches in patients with ulcerative colitis: A prospective, multicenter study. J Gastroenterol Hepatol. 2020;35(7):1143–1149.
   PubMed Web of Science ®Google Scholar
• Iacucci M, Kiesslich R, Gui X, et al. Beyond white light: optical enhancement in conjunction with magnification colonoscopy for the assessment of mucosal healing in ulcerative colitis. Endoscopy. 2017;49(06):553–559.
   PubMed Web of Science ®Google Scholar
• Moriichi K, Fujiya M, Okumura T. The endoscopic diagnosis of mucosal healing and deep remission in inflammatory bowel disease. Digestive endoscopy [Internet]; 2021 [cited 2021 May 22]. Available from: https://doi.org/https://doi.org/10.1111/den.13863.
   Google Scholar
• Wallace MB, Kiesslich R. Advances in endoscopic imaging of colorectal neoplasia. Gastroenterology. 2010;138(6):2140–2150.
   PubMed Web of Science ®Google Scholar
• Neumann H, Fuchs FS, Vieth M, et al. Review article: in vivo imaging by endocytoscopy. Aliment Pharmacol Ther. 2011;33(11):1183–1193.
   PubMed Web of Science ®Google Scholar
• Buchner AM. Confocal laser endomicroscopy in the evaluation of inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(8):1302–1312.
   PubMed Web of Science ®Google Scholar
• Bessho R, Kanai T, Hosoe N, et al. Correlation between endocytoscopy and conventional histopathology in microstructural features of ulcerative colitis. J Gastroenterol. 2011;46(10):1197–1202.
   PubMed Web of Science ®Google Scholar
• Watanabe O, Ando T, Maeda O, et al. Confocal endomicroscopy in patients with ulcerative colitis. J Gastroenterol Hepatol. 2008;23 Suppl 2:S286–S290.
   PubMed Web of Science ®Google Scholar
• Quénéhervé L, David G, Bourreille A, et al. Quantitative assessment of mucosal architecture using computer-based analysis of confocal laser endomicroscopy in inflammatory bowel diseases. Gastrointest Endosc. 2019;89(3):626–636.
   PubMed Web of Science ®Google Scholar
• Li C-Q, Liu J, Ji R, et al. Use of confocal laser endomicroscopy to predict relapse of ulcerative colitis. BMC Gastroenterol. 2014;14(1):45.
   PubMed Web of Science ®Google Scholar
• Buda A, Hatem G, Neumann H, et al. Confocal laser endomicroscopy for prediction of disease relapse in ulcerative colitis: a pilot study. J Crohns Colitis. 2014;8(4):304–311.
   PubMed Web of Science ®Google Scholar
• Kiesslich R, Duckworth CA, Moussata D, et al. Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut. 2012;61(8):1146–1153.
   PubMed Web of Science ®Google Scholar
• Ueda N, Isomoto H, Ikebuchi Y, et al. Endocytoscopic classification can be predictive for relapse in ulcerative colitis. Medicine. 2018;97(10):e0107.
   PubMed Web of Science ®Google Scholar
• Nishiyama S, Oka S, Tanaka S, et al. Clinical usefulness of endocytoscopy in the remission stage of ulcerative colitis: a pilot study. J Gastroenterol. 2015;50(11):1087–1093.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Van Assche G, Rutgeerts P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol. 2005;2(12):580–586.
   PubMedGoogle Scholar
• Kushner I. C-reactive protein and the acute-phase response. Hosp Pract. 1990;25(3A)16,:13, 16, 21–8.
   Web of Science ®Google Scholar
• Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol. 2015;21:11246–11259.
   PubMed Web of Science ®Google Scholar
• Menees SB, Powell C, Kurlander J, et al. A Meta-Analysis of the utility of C-Reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110(3):444–454.
   PubMed Web of Science ®Google Scholar
• Saverymuttu SH, Hodgson HJ, Chadwick VS, et al. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut. 1986;27(7):809–813.
   PubMed Web of Science ®Google Scholar
• Henriksen M, Jahnsen J, Lygren I, IBSEN Study Group, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57(11):1518–1523.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55(3):426–431.
   PubMed Web of Science ®Google Scholar
• Langhorst J, Boone J, Lauche R, et al. Faecal lactoferrin, calprotectin, PMN-elastase, CRP, and white blood cell count as indicators for mucosal healing and clinical course of disease in patients with mild to moderate ulcerative colitis: Post hoc analysis of a prospective clinical trial. ECCOJC. 2016;10(7):786–794.
   Web of Science ®Google Scholar
• Däbritz J, Langhorst J, Lügering A, et al. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12. Inflamm Bowel Dis. 2013;19:1130–1138.
   PubMed Web of Science ®Google Scholar
• Stamp TCB, Haddad JG, Twigg CA. Comparison of oral 25-hydroxycholecalciferol, vitamin D, and ultraviolet light as determinants of circulating 25-hydroxyvitamin d. The Lancet. 1977;309(8026):1341–1343.
   Google Scholar
• Gubatan J, Chou ND, Nielsen OH, et al. Systematic review with meta-analysis: association of vitamin D status with clinical outcomes in adult patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2019;50(11–12):1146–1158.
   PubMed Web of Science ®Google Scholar
• Adams JS, Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab. 2008;4(2):80–90.
   PubMedGoogle Scholar
• Cantorna MT, Rogers CJ, Arora J. Aligning the paradoxical role of vitamin D in gastrointestinal immunity. Trends Endocrinol Metab. 2019;30(7):459–466.
   PubMed Web of Science ®Google Scholar
• Gubatan J, Moss AC. Vitamin D in inflammatory bowel disease: more than just a supplement. Curr Opin Gastroenterol. 2018;34(4):217–225.
   PubMed Web of Science ®Google Scholar
• López-Muñoz P, Beltrán B, Sáez-González E, et al. Influence of vitamin D deficiency on inflammatory markers and clinical disease activity in IBD patients. Nutrients. 2019;11(5):1059.
   PubMed Web of Science ®Google Scholar
• Gubatan J, Mitsuhashi S, Zenlea T, et al. Low serum vitamin D during remission increases risk of clinical relapse in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2017;15(2):240–246.e1.
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Vitamin D levels and outcomes in inflammatory bowel disease-which is the chicken and which is the egg? Clin Gastroenterol Hepatol. 2017;15(2):247–248.
   PubMed Web of Science ®Google Scholar
• Cioffi M, Rosa AD, Serao R, et al. Laboratory markers in ulcerative colitis: current insights and future advances. World J Gastrointest Pathophysiol. 2015;6(1):13–22.
   PubMedGoogle Scholar
• Wu H, Wei J, Li J, et al. Serum procalcitonin as a potential early predictor of short-term outcomes in acute severe ulcerative colitis. Dig Dis Sci. 2019;64(11):3263–3273.
   PubMed Web of Science ®Google Scholar
• Azad S, Sood N, Sood A. Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study. Saudi J Gastroenterol. 2011;17(3):194–198.
   PubMed Web of Science ®Google Scholar
• Nakarai A, Kato J, Hiraoka S, et al. An elevated platelet count increases the risk of relapse in ulcerative colitis patients with mucosal healing. Gut Liver. 2018;12(4):420–425.
   PubMed Web of Science ®Google Scholar
• Uchihara M, Kato J, Tsuda S, et al. Blood biomarkers reflect integration of severity and extent of endoscopic inflammation in ulcerative colitis. JGH Open. 2017;1(3):98–104.
   PubMed Web of Science ®Google Scholar
• Yamaguchi S, Takeuchi Y, Arai K, et al. Fecal calprotectin is a clinically relevant biomarker of mucosal healing in patients with quiescent ulcerative colitis. J Gastroenterol Hepatol. 2016;31(1):93–98.
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448–454.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Shimoyama T, Umegae S, et al. Endoscopic score vs. fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing. Clin Transl Gastroenterol. 2018;9(3):136.
   PubMed Web of Science ®Google Scholar
• Leppkes M, Neurath MF. Cytokines in inflammatory bowel diseases - Update 2020. Pharmacol Res. 2020;158:104835.
   PubMed Web of Science ®Google Scholar
• Krzystek-Korpacka M, Kempiński R, Bromke M, et al. Biochemical biomarkers of mucosal healing for inflammatory bowel disease in adults. Diagnostics. 2020;10(6):367.
   Web of Science ®Google Scholar
• Shinzaki S, Matsuoka K, Iijima H, et al. Leucine-rich alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis. J Crohn’s Colitis. 2017;11(1):84–91.
   Google Scholar
• Nakov R, Velikova T, Nakov V, et al. Trefoil factor 3 is highly predictive of complete mucosal healing independently and in combination with C-reactive protein in patients with ulcerative colitis. JGLD. 2019;28:169–174.
   PubMed Web of Science ®Google Scholar
• Diaz-Jimenez L, Nunez LE, Beltran CJ, et al. Soluble ST2: a new and promising activity marker in ulcerative colitis. World J Gastroenterol. 2011;17:2181–2190.
   PubMed Web of Science ®Google Scholar
• Budzyńska A, Nowakowska-Duława E, Gawron-Kiszka M, et al. P189 serum neutrophil gelatinase-associated lipocalin correlates with Mayo clinic score in ulcerative colitis but fails to predict activity in crohn’s disease. J Crohn’s Colitis. 2017;11(suppl_1):S172–S172.
   Google Scholar
• Jung YS, Park JJ, Kim SW, Hong SP, Kim TI, et al. Correlation between soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel diseases. Dig Liver Dis. 2012;44(11):897–903.
   PubMedGoogle Scholar
• Guignard F, Mauel J, Markert M. Identification and characterization of a novel human neutrophil protein related to the S100 family. Biochem J. 1995;309(2):395–401.
   PubMed Web of Science ®Google Scholar
• Lopez RN, Leach ST, Lemberg DA, et al. Fecal biomarkers in inflammatory bowel disease. J Gastroenterol Hepatol. 2017;32(3):577–582.
   PubMed Web of Science ®Google Scholar
• Ayling RM, Kok K. Fecal calprotectin. Adv Clin Chem. 2018;87:161–190.
   PubMed Web of Science ®Google Scholar
• Voganatsi A, Panyutich A, Miyasaki KT, et al. Mechanism of extracellular release of human neutrophil calprotectin complex. J Leukoc Biol. 2001;70(1):130–134.
   PubMed Web of Science ®Google Scholar
• Røseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992;27(9):793–798.
   PubMed Web of Science ®Google Scholar
• Cury DB, Mizsputen SJ, Versolato C, et al. Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis. Cell Immunol. 2013;282(1):66–70.
   PubMed Web of Science ®Google Scholar
• Malham M, Carlsen K, Riis L, et al. Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative colitis. Scand J Gastroenterol. 2019;54(10):1214–1219.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19:332–341.
   PubMed Web of Science ®Google Scholar
• Hamanaka S, Nakagawa T, Hiwasa T, et al. Investigation of novel biomarkers for predicting the clinical course in patients with ulcerative colitis. J Gastroenterol Hepatol. 2018;33(12):1975–1983.
   PubMed Web of Science ®Google Scholar
• Li J, Zhao X, Li X, et al. Systematic review with meta-analysis: fecal calprotectin as a surrogate marker for predicting relapse in adults with ulcerative colitis. Mediators Inflamm. 2019;2019:2136501.
   PubMed Web of Science ®Google Scholar
• Stevens TW, Gecse K, Turner JR, et al. Diagnostic accuracy of fecal calprotectin concentration in evaluating therapeutic outcomes of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020;19(11):2333-2342.
   Web of Science ®Google Scholar
• Schoepfer AM, Beglinger C, Straumann A, et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009;15(12):1851–1858.
   PubMed Web of Science ®Google Scholar
• Scaioli E, Scagliarini M, Cardamone C, et al. Clinical application of faecal calprotectin in ulcerative colitis patients. Eur J Gastroenterol Hepatol. 2015;27:1418–1424.
   PubMed Web of Science ®Google Scholar
• Kostas A, Siakavellas SI, Kosmidis C, et al. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. WJG. 2017;23(41):7387–7396.
   PubMed Web of Science ®Google Scholar
• Lasson A, Öhman L, Stotzer P-O, et al. Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: a prospective, randomized, controlled study. United European Gastroenterol J. 2015;3(1):72–79.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Shimoyama T, Matsumoto K. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis. Aliment Pharmacol Ther. 2015;42(5):549–558.
   PubMed Web of Science ®Google Scholar
• Kato J, Hiraoka S, Nakarai A, et al. Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin? Intest Res. 2016;14(1):5–14.
   PubMed Web of Science ®Google Scholar
• Hiraoka S, Kato J, Nakarai A, et al. Consecutive measurements by faecal immunochemical test in quiescent ulcerative colitis patients can detect clinical relapse. J Crohns Colitis. 2016;10(6):687–694.
   PubMed Web of Science ®Google Scholar
• Nakarai A, Kato J, Hiraoka S, et al. Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse. World J Gastroenterol. 2016;22(21):5079–5087.
   PubMed Web of Science ®Google Scholar
• Nakarai A, Kato J, Hiraoka S, et al. Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test. Am J Gastroenterol. 2013;108(1):83–89.
   PubMed Web of Science ®Google Scholar
• Dai C, Jiang M, Sun M-J, et al. Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: a systematic review and Meta-analysis. J Gastroenterol Hepatol. 2018;33(5):990–997.
   PubMed Web of Science ®Google Scholar
• Ishida N, Miyazu T, Matsuura T, et al. Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker. Int J Colorectal Dis. 2020;35(9):1729–1739.
   PubMed Web of Science ®Google Scholar
• Nakarai A, Hiraoka S, Takahashi S, et al. Simultaneous measurements of faecal calprotectin and the faecal immunochemical test in quiescent ulcerative colitis patients can stratify risk of relapse. J Crohns Colitis. 2018;12(1):71–76.
   PubMed Web of Science ®Google Scholar
• Ryu DG, Kim HW, Park SB, et al. Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis. Medicine (Baltimore. 2019;98(36):e17080.
   PubMed Web of Science ®Google Scholar
• Hiraoka S, Inokuchi T, Nakarai A, et al. Fecal immunochemical test and fecal calprotectin results show different profiles in disease monitoring for ulcerative colitis. Gut Liver. 2018;12(2):142–148.
   PubMed Web of Science ®Google Scholar
• Kim ES, Lee HS, Kim SK, Kim EY, Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD), et al. Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study. Scand J Gastroenterol. 2020;55(2):163–168.
   PubMed Web of Science ®Google Scholar
• Takashima S, Kato J, Hiraoka S, et al. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin Vs. Fecal immunochemical test. Am J Gastroenterol. 2015;110(6):873–880.
   PubMed Web of Science ®Google Scholar
• Uchida K, Matsuse R, Tomita S, et al. Immunochemical detection of human lactoferrin in feces as a new marker for inflammatory gastrointestinal disorders and Colon cancer. Clin Biochem. 1994;27(4):259–264.
   PubMed Web of Science ®Google Scholar
• Guerrant RL, Araujo V, Soares E, et al. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin Microbiol. 1992;30(5):1238–1242.
   PubMed Web of Science ®Google Scholar
• Sugi K, Saitoh O, Hirata I, et al. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol. 1996;91(5):927–934.
   PubMed Web of Science ®Google Scholar
• Foell D, Wittkowski H, Ren Z, et al. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol. 2008;216(2):183–192.
   PubMed Web of Science ®Google Scholar
• Walker TR, Land ML, Kartashov A, et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44(4):414–422.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Bermejo F, Pérez-Calle J-L, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009;15:1190–1198.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Shiraki M, Bamba T, et al. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis. 2014;29(4):485–491.
   PubMed Web of Science ®Google Scholar
• Dai C, Jiang M, Sun M-J. Fecal markers in the management of inflammatory bowel disease. Postgrad Med. 2018;130(7):597–606.
   PubMed Web of Science ®Google Scholar
• Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in crohn’s disease. Gut. 2005;54(3):364–368.
   PubMed Web of Science ®Google Scholar
• Stidham RW, Liu W, Bishu S, et al. Performance of a deep learning model vs human reviewers in grading endoscopic disease severity of patients with ulcerative colitis. JAMA Netw Open. 2019;2(5):e193963.
   PubMed Web of Science ®Google Scholar
• Liu F, Lee SA, Riordan SM, et al. Global studies of using fecal biomarkers in predicting relapse in inflammatory bowel disease. Front Med. 2020;7(580803):580803.
   Web of Science ®Google Scholar
• Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103(1):162–169.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Peyrin-Biroulet L, Danese S, et al. Approaches to integrating biomarkers into clinical trials and care pathways as targets for the treatment of inflammatory bowel diseases. Gastroenterology. 2019;157(4):1032–1043.e1.
   PubMed Web of Science ®Google Scholar
• Cozijnsen MA, Ben Shoham A, Kang B, et al. Development and validation of the mucosal inflammation noninvasive index for pediatric Crohn’s disease. Clin Gastroenterol Hepatol. 2020;18(1):133–140.e1.
   PubMed Web of Science ®Google Scholar
• Puolanne A-M, Kolho K-L, Alfthan H, et al. Rapid fecal calprotectin test and symptom index in monitoring the disease activity in colonic inflammatory bowel disease. Dig Dis Sci. 2017;62(11):3123–3130.
   PubMed Web of Science ®Google Scholar
• Sollelis E, Quinard RM, Bouguen G, et al. Combined evaluation of biomarkers as predictor of maintained remission in crohn’s disease. WJG. 2019;25(19):2354–2364.
   PubMed Web of Science ®Google Scholar
• Bodelier AGL, Jonkers D, van den Heuvel T, et al. High percentage of IBD patients with indefinite fecal calprotectin levels: Additional value of a combination score. Dig Dis Sci. 2017;62(2):465–472.
   PubMed Web of Science ®Google Scholar
• Floer M, Clausen M, Meister T, et al. Soluble syndecan-1 as marker of intestinal inflammation: a preliminary study and evaluation of a new panel of biomarkers for non-invasive prediction of active ulcerative colitis. Adv Clin Exp Med. 2021;30(7):655–660.
   PubMed Web of Science ®Google Scholar